Previous studies have shown that topiramate is effective in preventing migraine headaches. This is a 6-month observational study to evaluate the safety of topiramate in the prevention of migraine in adult patients. The study duration is 6-months, with 5 study visits during the study. The dosage of topiramate should then be increased at 1-week intervals by increments of 25 mg daily. If the patient is unable to tolerate the individualized regimen, longer intervals between doses increments may be used. The recommended total daily dose of topiramate treatment for the prevention of migraine is 100mg daily administered in two divided doses. Some patients may benefit from the total daily dose of 50mg daily. There are patients who received a total daily dose of up to 200mg daily. Dose and individualization rate should be determined by the clinical outcome. The primary objective of this study is the collection and evaluation of data on the safety of topiramate in the prevention of migraine in adult patients over 6 months.

Topiramate will be administered according to the physician's prescription; dose and individualization rate (rate at which the dose of topiramate would be increased) will be determined by the clinical outcome.